Turinabol
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Lean dry muscle gain, recomposition, strength retention, and non-tested athletic performance.
Treat Turinabol as a liver- and lipid-taxing oral AAS, not a mild shortcut. Tested athletes should avoid it entirely because long-term metabolites can be career-ending at any dose.
Lean dry muscle gain, recomposition, strength retention, and non-tested athletic performance. The useful niche is dry progress without estrogenic water gain, plus SHBG displacement that can increase the free fraction of testosterone in a stack.
The big risks are 17α-alkylated liver strain, HDL/LDL damage, HPG-axis suppression requiring PCT, and long-term-metabolite detection. ALT/AST can rise 2-3x ULN by week 4, and a single 5 mg dose produced 9.9-44.9 day WADA detection in controlled data.
Turinabol is valued when the target is dry, retainable progress rather than fast scale weight. Its best-supported community niche is a bounded oral add-on to testosterone or TRT where SHBG displacement, no aromatization, and no DHT conversion matter. The tradeoff is not mild: it is still a 17α-alkylated oral with liver, lipid, suppression, and anti-doping liabilities.
Moderate-to-high for lean mass and recomp, high for strength retention and non-tested athletic utility, and low for raw mass compared with testosterone, dianabol, or nandrolone. Community posture is bullish but bounded: useful for dry performance goals, not a beginner shortcut or a high-mass bulking drug.
Never combine with another 17α-alkylated oral (winstrol, dbol, anadrol, anavar) — combined hepatotoxicity is additive and has caused peliosis hepatis and acute liver failure.
Intro
Turinabol (4-chlorodehydromethyltestosterone; 4-CDMT) is a synthetic oral androgen developed by Jenapharm in East Germany in 1962.
Unlike virtually every other AAS — which were initially developed as medical therapies and repurposed for performance enhancement — turinabol was engineered from the outset for athletic performance improvement under the East German state sport program (Staatsplanthema 14.25). Jenapharm achieved this by modifying testosterone with two structural changes: the 4-chloro substitution at ring position 4 (eliminating aromatization and substantially reducing 5α-reduction) and the 17α-methyl group (enabling oral bioavailability at the cost of hepatotoxicity).
The compound was deployed in the GDR doping program from 1968 to 1989, administered to approximately 10,000 athletes across swimming, sprinting, rowing, and field sports — often without their knowledge or consent. Doses ranged from 5 to 35 mg/day. The program was dismantled at German reunification in 1989, and Jenapharm discontinued production. Turinabol has never been FDA-approved and is not commercially manufactured today — all circulating supply is unregulated supply-produced.
Turinabol's primary pharmacodynamic mechanism is SHBG (sex hormone-binding globulin) displacement: it binds SHBG competitively with endogenous testosterone, releasing previously bound testosterone into the biologically active free fraction. This mechanism classifies it as a Class 2 AAS in the Llewellyn system — operating predominantly through non-AR pathways — and explains its synergy with all testosterone-containing stacks. Additionally, turinabol has documented fibrinolytic capacity-enhancing effects (increases the body's ability to dissolve blood clots), a property unique among common AAS and one that contributes directly to its endurance benefit in GDR athletes.
LTM (long-term metabolite) WADA testing, developed post-2002 using preserved Olympic urine samples, now detects tbol-specific epoxide metabolites for 9–45 days from a single 5 mg dose and months to years at performance doses. This effectively renders turinabol unusable for any athlete subject to anti-doping testing.
Observed Effects
Lean, dry muscle gains are the defining outcome of turinabol use. Unlike dianabol (which produces rapid scale gains driven largely by water and glycogen), tbol's gains are characteristically dry and high-quality — the canonical community data point is 1 lb scale gain with 1 inch waist reduction over 3 weeks at 50 mg/day. Full cycle outcomes (6–8 weeks, 40–60 mg/day): 4–8 lb lean mass retained post-cycle with minimal water. Post-cycle retention rates are substantially higher than wetter compounds; in a direct comparison from one experienced user, dbol gained 15 lb / kept 6 lb, while tbol gained 7 lb / kept 6.5 lb.
SHBG displacement is mechanistically confirmed and produces a measurable increase in free testosterone fraction when tbol is added to any testosterone-containing stack — without changing total testosterone levels. This mechanism provides genuine stacking synergy beyond tbol's direct anabolic activity.
Endurance enhancement is unique among oral AAS. The GDR program specifically included endurance athletes (swimmers, rowers, middle-distance runners) who responded favorably. Jenapharm research documented fibrinolytic capacity increases — a property not shared by other common AAS, which generally do not improve fibrinolysis. Community educators attribute tbol's endurance benefit to this mechanism rather than hematocrit elevation.
Strength increases onset rapidly (days 5–14 for first effects per practitioner reports) and are predominantly retained post-cycle. One steroid.com user logging an 8-week 50 mg/day cycle reported all strength gains intact 8 weeks post-cycle. The speed of strength onset makes tbol effective as a kickstart compound while waiting for long-ester testosterone to peak.
Vascularity and muscle hardness improvements appear before scale weight moves. Multiple experience logs document looking leaner and more vascular in weeks 3–4 before meaningful scale gains appear. The absence of subcutaneous water retention is the primary driver of this visual effect.
Appetite amplification is consistently reported in weeks 1–3, attributed to SHBG displacement increasing free androgens. Most users consider it beneficial during mass phases. Mild mood elevation and training motivation increase are reported as performance-enhancing effects; severe aggression is rarely documented at typical doses.
Field Reports
Community experience reports are remarkably consistent across 20 years of public performance-community documentation (2005–present), providing reasonable confidence in tbol's characteristic outcomes.
The defining positive theme across all experience logs is the lean, dry nature of gains and their high post-cycle retention rate — the dry gains (no glycogen/water component) retain at a substantially higher percentage than wetter compounds.
The canonical recomp signal — 1 lb scale gain with 1 inch waist reduction over the first 3 weeks at 50 mg/day — has been cited so consistently across multiple independent reports that it has become community shorthand for tbol's mechanism. Practitioners consistently describe the physique-first, scale-second pattern: vascularity and muscle hardness appear in weeks 3–4 before scale weight moves, distinguishing tbol from dbol (scale jumps first due to water) and from winstrol (no anabolic drive).
Strength retention is a consistent positive: multiple logs document strength gains intact 8 weeks post-cycle. One 8-week 50 mg/day public log explicitly noted retained strength after the cycle. This retention pattern is attributed to the gain quality — lean tissue vs fluid — and is a primary driver of experienced users returning to tbol after experimenting with higher-water compounds.
On the negative side, shoulder and lower-back pumps at 50+ mg/day are the most frequently cited limiting intra-workout side effect — not the desirable bodybuilder pump, but painful blood pooling that limits range of motion. Heartburn emerging at weeks 6–8 is a characteristic late-cycle signal described in multiple independent logs and is widely recognized as the appropriate cycle-termination indicator. One user ended his 30 mg/day cycle at week 7 due to daily heartburn that had become limiting.
The dose sweet spot debate has been effectively settled in community literature: 40–60 mg/day clearly outperforms 25–30 mg/day (multiple direct comparisons), while 80 mg/day adds hepatotoxicity without proportional benefit. The community consensus on cycle length — 6 weeks preferred, 8 weeks absolute maximum — has held constant for 15+ years and is backed by the consistent late-cycle GI distress and LFT elevation data.
Community Consensus
Turinabol occupies a historically unique and respected niche in the performance-enhancement community.
It is the only AAS developed specifically for athletic performance as its primary purpose — not repurposed from a medical therapy. The GDR Staatsplanthema 14.25 program (1968–1989) deployed it to approximately 10,000 East German Olympic athletes across swimming, sprinting, rowing, and field events. Female athletes received doses in the 10–35 mg/day range, often from age 16 onward, sometimes without their knowledge — told the tablets were vitamins. The systematic virilization harm to female athletes was documented extensively in post-reunification Stasi files and athlete testimony, and remains the most comprehensive natural experiment on androgen virilization in women ever conducted.
In contemporary community positioning, tbol is not the compound of choice for rapid mass building. Community educators consistently rate it C-tier or below in bodybuilding mass rankings — acknowledging it is effective but inferior to testosterone, dianabol, or nandrolone for sheer scale weight. However, its valuation rises dramatically when evaluated for its intended use: lean gains, athletic performance, recomp, and SHBG displacement in stacks. One corpus educator described it as 'the compound that does exactly what it says it does — dry lean gains, endurance improvement, SHBG clearing, no estrogen, no DHT. It doesn't surprise you.' The same educator rates it the first choice oral to add to TRT, preferred over anavar and proviron because it amplifies free testosterone without competing at the androgen receptor.
The LTM detection watershed changed the compound's role permanently. WADA's post-2002 development of turinabol-specific LTM testing — enabled by re-analysis of preserved Olympic urine samples — resulted in medal revocations from competitions held over a decade prior. The Loke et al. 2021 controlled administration study formalized detection window data: 9.9–44.9 days from a single 5 mg dose, with performance doses extrapolating to months or years. Tbol effectively disappeared from use in tested sport after this, cementing its current status as exclusively a non-tested performance community compound.
Current non-medical supply is outside regulated pharmaceutical channels, with highly variable quality and frequent counterfeiting. The Jenapharm brand referenced historically has not been commercially produced since 1989.
Risks & Monitoring
Hepatotoxicity is the primary and most clinically significant adverse effect. It is driven by the 17α-methyl group, not the steroid backbone — the 4-chloro modification does NOT reduce liver burden, a misconception directly corrected by experienced community educators. At equivalent doses, tbol liver impact is similar to dianabol. ALT and AST elevation to 2–3× upper normal range is documented in bloodwork reports at 4 weeks. At 80 mg/day, ALT elevation to approximately 5× ULN has been reported by week 6. All hepatotoxicity in documented logs has been reversible post-cycle with TUDCA support and appropriate cycle length. Mandatory monitoring: LFTs at baseline and week 4; stop if ALT/AST >3× ULN.
Cardiovascular impact includes HDL suppression of 15–25% from baseline, with LDL rising 10–20%, documented across multiple bloodwork reports. This is moderate compared to winstrol (HDL suppression 50%+) but real and cumulative with cycle length. Two-oral stacks amplify lipid risk — one UK-Muscle user's anavar + tbol log documented worsened lipid panel compared to either compound solo. Lipid values return to baseline within 8 weeks post-cycle with omega-3 supplementation.
HPG axis suppression is real despite community perception of tbol as 'mild.' LH and FSH suppression occurs on solo tbol cycles. One corpus educator explicitly stated: 'If you run solo tbol for 6–8 weeks, you need PCT. Your LH and FSH will be suppressed. It's not as complete a shutdown as testosterone propionate but it's real suppression that warrants SERM treatment.' With proper SERM PCT (starting 24–48 hours after the last dose, enabled by tbol's 16-hour half-life), testosterone, LH, and FSH recover within 6–8 weeks. Without PCT, recovery extends 10–16 weeks per community bloodwork comparisons. A testicular Leydig cell carcinoma case was reported in a young weightlifter after 5 years of intermittent tbol use — the only published carcinoma case specifically linked to tbol.
Muscle pumps (painful, range-of-motion limiting) in the lower back and shoulders are the most commonly cited limiting intra-workout side effect at doses above 50 mg/day. Taurine supplementation (3–5 g/day) is the standard mitigation. Unlike winstrol, tbol does not cause joint drying — it is specifically preferred by athletes with joint sensitivity.
Hair loss risk is substantially reduced (but not eliminated) by the 4-chloro modification blocking 5α-reduction. Documented at 30 mg/day without pharmacological protection (onset week 4, reversed post-cycle). With finasteride + spironolactone at 30 mg/day: no hair loss documented. Acne is mild at typical doses, more common at 60+ mg/day. No gynecomastia from tbol alone (no aromatization; progesterone receptor activity partial and mild).
Gastrointestinal disturbance — specifically heartburn — is a late-cycle side effect reported in weeks 6–8. One user running 30 mg/day ended his cycle at week 7 due to daily heartburn. Another reported severe gas in weeks 1–2 at 50 mg/day. GI distress signals accumulating hepatic and gastric irritation from the 17α-alkylated tablet. Taking tbol with food reduces acute irritation.
Adrenal enzyme inhibition: tbol inhibits mitochondrial steroidogenic CYP enzymes (CYP11B2, CYP11B1) in vitro, with strongest inhibition at CYP11B2 — the enzyme catalyzing the final step in aldosterone synthesis. At oral performance doses, whether systemic concentrations are sufficient to meaningfully affect adrenal steroidogenesis is not established. Adrenal insufficiency has not been reported in community literature. This remains a theoretical concern for high-dose, long-duration use.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Mandatory before starting any 17α-alkylated oral. Establishes normal values for comparison at the 4-week checkpoint. Existing elevated LFTs contraindicate tbol use.
4-week midcycle check is mandatory for all tbol cycles. ALT/AST >3× ULN = stop immediately. 2–3× ULN is expected and manageable; 5× ULN as documented at 80 mg/day requires immediate termination.
HDL suppression 15–25% is documented on tbol. Baseline required to quantify suppression magnitude and assess cardiovascular risk. Disqualifying if baseline HDL is already low.
At 4-week check alongside LFTs. Critical when running alongside another oral — two-oral stacks amplify lipid risk substantially.
Establishes HPG axis baseline before suppression. Required for PCT planning — defines the recovery target. Essential for solo tbol cycles where suppression is complete without added testosterone.
At PCT start (24–48 hrs after last dose) and 6 weeks post-PCT. Confirms HPG recovery. With SERM PCT: recovery expected 6–8 weeks. Without PCT: may extend 10–16 weeks.
Baseline hematocrit and hemoglobin. Tbol does not typically elevate hematocrit (unlike EQ or testosterone), but baseline establishes context for any changes during cycle.
Baseline renal function and electrolytes. Relevant given tbol's documented adrenal CYP enzyme interactions in vitro. Includes glucose baseline.
For males over 40 or with family history of prostate cancer. Tbol's reduced androgenicity is a theoretical prostate advantage over testosterone, but baseline data is prudent before any androgen exposure.
Avoid With
Do not combine Turinabol with the following. Sorted highest-severity first.
Why:Two concurrent 17aa orals produce additive hepatotoxicity that is not simply proportional to dose — the combination substantially elevates risk of cholestatic jaundice, peliosis hepatis, and acute liver injury. Case reports of severe hepatotoxicity in oral-only stacks are well-documented in clinical literature. This is the highest-priority contraindication for tbol.
What to do:Sequential use (different phases, with liver enzyme normalization between) is acceptable. Concurrent use is not.
Why:LTM (long-term metabolite) WADA testing detects tbol-specific epoxide metabolites 9.9–44.9 days from a single 5 mg dose (Loke et al. 2021). At performance doses (20–80 mg/day for 6–8 weeks), estimated detection window is months to years. Olympic sample retesting has revoked medals from competitions held over a decade prior. There is no safe minimum dose.
What to do:Career-ending risk for tested athletes at any dose. This is not a timing or threshold issue — the LTM protocol makes tbol intrinsically incompatible with tested competition under any currently available WADA protocol.
Why:Alcohol is independently hepatotoxic. Combined with 17α-alkylation liver stress, even moderate intake significantly elevates ALT/AST and increases acute liver injury risk. Liver's metabolic capacity for tbol is reduced when competing with alcohol metabolism.
What to do:Complete alcohol abstinence required during tbol cycles. Non-negotiable.
Why:Tbol competes with multiple hepatic CYP enzymes. Concurrent CYP-substrate or CYP-inhibiting drugs can elevate both tbol plasma levels and the competing drug's levels, amplifying hepatotoxic load. Standard-dose acetaminophen (Tylenol) adds meaningful additional liver stress on top of 17α-alkylation.
What to do:Disclose steroid use to treating physicians. Avoid unnecessary acetaminophen — use ibuprofen for pain where renal function is normal. Alert pharmacist to AAS use when filling any prescription.
Why:Tbol has partial progesterone receptor activity. When stacked with nandrolone (a potent progestogen and prolactin elevator), the progesterone receptor activity may compound nandrolone's prolactin-stimulating effects. Monitor prolactin and have cabergoline on hand when running tbol with any 19-nor compound.
What to do:Not a prohibition — tbol + nandrolone is a commonly used synergistic stack. A monitoring requirement, not a contraindication.
Protocols By Goal
Lean bulk: Turinabol 40–50 mg/day + Testosterone Enanthate/Cypionate 400–500 mg/week for 12 weeks, with tbol run as a kickstart (weeks 1–6) while the long-ester testosterone builds.
The SHBG displacement from tbol amplifies free testosterone from the injectable during the build phase. Drop tbol at week 6 when testosterone peaks. Expected: 4–8 lb lean, keeper mass from the tbol phase plus the sustained base from injectable testosterone.
Recomposition: Turinabol 40–50 mg/day + Testosterone 200–250 mg/week (TRT-level base) at maintenance calories for 8 weeks. Tbol's Class 2 mechanism combined with low-dose testosterone creates conditions for simultaneous fat loss and lean mass gain. Scale weight moves minimally; physique changes are measured in photos and tape measure. Canonical outcome: approximately 1 lb scale gain with 1 inch waist reduction in the first 3 weeks.
Cutting: Turinabol 40–50 mg/day + Testosterone Propionate 300 mg/week during caloric deficit for 6–8 weeks. Tbol preserves lean mass during a deficit without adding water. Preferred over winstrol for users with joint sensitivity. No aromatization avoids the need for AI during the cut.
Endurance/Athletic performance (non-tested competition only): 20–30 mg/day solo or with minimal testosterone for 4–6 weeks pre-event. Low-dose tbol for the fibrinolytic capacity and endurance enhancement without significant mass gain. Weight-class athletes benefit from strength gain without scale weight increase. CRITICAL: LTM detection window is months to years at performance doses — this use is career-ending for any tested athlete.
TRT add-on: 20–40 mg/day cyclically (6 weeks on, 6–8 weeks off) for TRT patients seeking anabolic enhancement. Tbol's Class 2 mechanism means it does not compete with testosterone at the androgen receptor — it amplifies testosterone's effect via SHBG displacement. Particularly valued by older males (50+) where SHBG is often elevated, producing greater SHBG-displacement benefit.
Primobolan stack ('gentlemen's stack'): Primobolan Depot 400 mg/week + Turinabol 40 mg/day (primobolan 12 weeks; tbol 6–8 weeks). Both compounds have low androgenicity and do not aromatize. Only tbol is 17α-alkylated — primobolan injectable adds no hepatic burden. Popular among users over 30 and image-conscious users. Slower gains than test + tbol but higher quality physique transformation.
Dosing Details
Male dosing follows a clear experience ladder. Beginners: 30–40 mg/day for 6 weeks, split twice daily (morning + pre-workout).
Intermediate: 40–60 mg/day for 6–8 weeks. Advanced: 60–80 mg/day for 6 weeks maximum — above 60 mg adds hepatotoxicity without proportional additional gains; 80 mg/day has produced ALT elevation to approximately 5× ULN by week 6 in documented logs. TRT add-on: 20–40 mg/day for 6–8 weeks on/off cycling (6 weeks on, 6–8 weeks off).
Female dosing: 2.5–5 mg/day as an assessment dose for the first 2 weeks; increase to 5–10 mg/day if no virilization signs emerge; hard ceiling 15 mg/day for experienced female users only; cycle length 4–6 weeks maximum. Monitor voice, clitoral sensitivity, and facial hair throughout — stop immediately if any virilization sign appears. The GDR program data (women given 10–35 mg/day without consent) provides the best evidence for the virilization ceiling: permanent voice changes and clitoral enlargement are documented at these higher doses.
Dosing split: twice-daily is preferred over once-daily despite the 16-hour half-life. Stable blood levels reduce peak-concentration side effects (heartburn, pump). Common split: 20 mg morning + 20 mg pre-workout for 40 mg/day total. Taking with food reduces GI irritation.
Cycle length hard limit: 8 weeks absolute maximum, 6 weeks preferred. At 8 weeks, a mandatory midcycle LFT check at week 4 is required — if ALT/AST >3× ULN, stop. Never run tbol (or any 17aa oral) continuously without an off-cycle period at minimum equal to the cycle length. Heartburn emerging at weeks 6–8 is a hepatic stress signal, not a transient tolerable side — it indicates cycle termination is appropriate.
Stacks & Alternatives
The foundational tbol stack. Testosterone provides AR-mediated anabolic drive and maintains HPG function; tbol displaces SHBG (increasing free testosterone) and adds Class 2 anabolic activity. These mechanisms are complementary and non-competing — tbol does not 'compete' with testosterone at the receptor. The SHBG displacement amplifies the active fraction of the injectable testosterone during the kickstart phase. Gold standard tbol stack with the best-documented outcomes. Typical: tbol 40–60 mg/day + test 300–500 mg/week.
Tbol (Class 2, SHBG displacement) + nandrolone (Class 1, high AR affinity) provides synergistic anabolic activity across two independent mechanisms. Tbol's SHBG displacement increases free nandrolone availability. Note: tbol's partial progesterone receptor activity may interact with nandrolone's progesterone-related effects — monitor prolactin and have cabergoline on hand. Testosterone base recommended in this stack. Typical: tbol 40–50 mg/day + NPP 300–400 mg/week.
EQ's RBC-increasing and endurance-enhancing properties complement tbol's fibrinolytic and SHBG-displacing effects. Both are dry and minimally estrogenic. EQ's slow onset (6–8 weeks to peak) makes tbol a natural kickstart. Combined: lean, slow-building, endurance-forward physique with vascularity. Excellent athletic performance stack. Typical: tbol 40–50 mg/day + EQ 400–600 mg/week.
Low-androgenicity, non-aromatizing pairing. Only tbol carries hepatotoxicity (primobolan injectable is not 17aa). The combination produces lean gains without androgenic, estrogenic, or joint side effects. Popular among older males and image-conscious users. Slower and more modest gains than test + tbol but significantly cleaner side effect profile. Typical: tbol 40 mg/day + primo depot 400 mg/week.
Trenbolone is the prototypical Class 1 compound (very high AR affinity) — synergy with tbol's Class 2 mechanism is maximal. The pre-contest hardening combination: trenbolone drives extreme hardening and nitrogen retention; tbol provides SHBG displacement and endurance support. Significant side effect burden from trenbolone. Tbol adds quality lean enhancement without additional androgenic load. Requires testosterone base. Typical: tbol 40–50 mg/day + tren ace 300–400 mg/week + testosterone base.
Proviron is not 17α-alkylated — minimal hepatotoxicity. Both compounds displace SHBG, producing additive free testosterone increase with complementary hardening effects. Total 17aa oral load is just tbol — a liver-friendly two-compound oral approach. Proviron adds libido support. Useful for TRT patients wanting dual SHBG displacement without a second 17aa compound. Typical: tbol 40 mg/day + proviron 25–50 mg/day.
Alternatives
Stack Cost
Turinabol is a high-tax oral add-on: cleaner-looking than wet mass orals, but it spends liver, lipid, HPG-axis, sourcing, female-virilization, and anti-doping capacity quickly.
The article treats 17α-alkylation as the primary clinical risk, with ALT/AST commonly rising by week 4 and higher-dose logs reaching roughly 5× ULN. Lipids also move: HDL suppression of 15–25% and LDL increases of 10–20% are described across bloodwork reports.
The article rejects the idea that solo tbol is suppression-free. LH/FSH suppression is expected after 6–8 week male cycles, and the article requires a SERM PCT plan plus post-cycle labs.
The article gives a 9.9–44.9 day detection window from a single 5 mg dose and extrapolates months-to-years exposure risk at performance doses. For tested athletes, this is a hard incompatibility rather than a timing problem.
The article's female evidence is dominated by GDR exposure and permanent virilization harms. Low-dose voluntary use exists in community reports, but voice change, clitoral enlargement, hair growth, and menstrual disruption are not acceptable routine tradeoffs.
Commercial Jenapharm supply ended in 1989. The article says all current supply is unregulated supply-produced, with counterfeit and underdosed tablets common enough that third-party HPLC testing is the only reliable verification path.
- ·Do not stack with another 17α-alkylated oral; the article treats concurrent oral hepatotoxicity as the clearest hard conflict.
- ·Budget liver and lipid capacity before adding cosmetic or performance upside. Baseline and week-4 LFT/lipid panels are part of the protocol, not optional cleanup.
- ·For tested athletes, tbol has zero practical capacity because long-term metabolite testing can identify exposure after a single 5 mg dose.
- ·Women should not treat the historical low-dose range as a recommendation; any virilization or menstrual signal means the risk tier has already changed.
- ·Heartburn in weeks 6–8 and painful pumps above 50 mg/day are execution signals, not proof that the dose is working better.
- ·Baseline and week-4 liver-function testing with a stop rule for ALT/AST above 3× ULN
- ·Baseline and midcycle fasting lipid panel, especially if any other androgen is present
- ·Male PCT planning with total/free testosterone, LH, and FSH recovery checks
- ·TUDCA/NAC-style liver support, taurine for pumps, and omega-3 support for lipid pressure
- ·Source verification through third-party testing or conservative interpretation of weak response
The article labels tbol intermediate because the apparent mildness is misleading: users still need lab access, PCT planning, identity verification, and a hard anti-doping screen.
- ·No access to baseline and midcycle bloodwork
- ·The goal is rapid raw mass rather than dry performance or recomp
- ·The user is a tested athlete at any level
- ·The plan includes another oral AAS
- ·The user is female and optimizing for longevity rather than accepting anabolic virilization risk
The 16-hour half-life makes discontinuation simple, and PCT can start 24–48 hours after the last dose. The harder off-ramp is biological: liver enzymes, lipids, and male HPG-axis markers still need documented recovery.
- ·ALT/AST remain elevated after stopping
- ·HDL/LDL lag subjective recovery
- ·Low-testosterone symptoms after solo or poorly supported male cycles
- ·Persistent female virilization signs if stop signals were ignored
- ·False reassurance from a short half-life despite long anti-doping metabolite detection
Treat week-4 bloodwork as a go/no-go checkpoint and stop if ALT/AST exceed the article's 3× ULN rule.
Avoid entirely. The article's LTM section makes this a hard incompatibility, not a clearance-timing decision.
Stop immediately at early signs. Do not complete the planned cycle once irreversible-risk signals appear.
Verify source quality before escalating. Third-party testing is the reliable route; weak response alone should not justify an 80 mg/day jump.
The article's main safety model depends on having liver and lipid capacity before adding a 17α-alkylated oral.
LTM detection can identify tbol from a single 5 mg dose and has driven retroactive sanctions.
The article lists additive hepatic stress as the highest-priority stacking conflict.
The article documents irreversible virilization and menstrual/fertility disruption as central female risks.
Practical Setup
Liver support is mandatory and non-negotiable for all tbol cycles. TUDCA (tauroursodeoxycholic acid) at 500 mg/day throughout the cycle and for 2–4 weeks post-cycle is the community standard for 17aa oral hepatoprotection.
NAC (N-Acetyl Cysteine) at 600–1200 mg/day provides complementary antioxidant support. Milk thistle (silymarin) is widely used but is considered insufficient as a sole hepatoprotectant for cycles longer than 4 weeks. Taurine at 3–5 g/day reduces the severity of lower-back and shoulder pumps. Omega-3 fatty acids at 3–5 g EPA+DHA/day partially mitigate HDL suppression.
PCT planning benefits from tbol's 16-hour half-life: PCT can start 24–48 hours after the last dose, compared to the 2-week wait required after long-ester testosterone. Standard SERM: Nolvadex 40 mg/day for 2 weeks → 20 mg/day for 2 weeks. Clomid alternative: 50/50/25/25 (each dose sustained for 1 week). Optional HCG: 500 IU/day for 10 days at cycle end before starting SERM (restores testicular volume and primes Leydig cells for SERM stimulation). Blood work at PCT start and 6 weeks post-PCT is strongly recommended to confirm hormonal recovery.
Cycle-off discipline: observe an off-cycle period at minimum equal to the on-cycle time before considering the next tbol or 17aa oral cycle. Liver enzymes should return to baseline before restarting. Multiple consecutive cycles without adequate washout are the mechanism behind rare severe hepatotoxicity cases in the literature.
Sourcing considerations: all available tbol is unregulated supply-produced. Counterfeit and underdosed product is common across all unregulated supply brands. No pharma-grade reference standard exists. Third-party HPLC testing through community testing services is the only reliable verification method. The original Jenapharm Oral-Turinabol has not been commercially manufactured since 1989 — any product sold under this name today is counterfeit.
For women, the GDR program data provides the best available virilization ceiling guidance. Community-established safe range: 5–10 mg/day, 4–6 weeks maximum, with immediate cessation at any virilization sign. Voice changes are the first irreversible signal and the non-negotiable stop criterion.
Mechanism Deep Dive
Turinabol (4-chlorodehydromethyltestosterone) differs from testosterone through two key structural modifications.
The 4-chloro substitution at ring position 4 blocks aromatase enzyme recognition (eliminating conversion to estrogen), substantially inhibits 5α-reductase activity (reducing DHT-analog production and thus androgenic side effects including hair loss and prostate stimulation), and reduces the compound's affinity for the androgen receptor — shifting its mechanism toward non-AR pathways. The 17α-methyl group confers oral bioavailability by resisting first-pass hepatic deactivation; this same mechanism underlies 17α-alkylation hepatotoxicity. A 1,2-double bond (inherited from its structural precursor methandrostenolone) further enhances the anabolic-to-androgenic ratio at the receptor level.
The primary pharmacodynamic mechanism in practice is SHBG displacement. Tbol binds SHBG competitively with endogenous testosterone, releasing previously bound testosterone into the biologically active free fraction. The Herburger injection bioassay documented anabolic potency 57.9–255.5% relative to testosterone (100%) with androgenic potency of only 6–9% — an anabolic:androgenic ratio of approximately 6:1 to 28:1 depending on the measured endpoint. In the Llewellyn classification system, this non-AR mechanism classifies tbol as a Class 2 AAS. Class 2 compounds (tbol, anadrol) complement Class 1 compounds (trenbolone, nandrolone, which have high AR affinity) synergistically — the two classes act through different pathways, making their combination more than additive.
Fibrinolytic capacity enhancement is documented in Jenapharm research and distinguishes tbol from all other common AAS. Tbol increases the body's ability to dissolve blood clots (fibrinolysis), a property not shared by other anabolic compounds that generally have neutral or negative effects on fibrinolytic markers. This mechanism provides a plausible explanation for the endurance benefits documented in GDR athletes beyond the simple anabolic effects.
Hepatic metabolism involves multiple CYP enzyme pathways. CYP11B2 demonstrates the highest catalytic efficiency for tbol metabolism (kcat/Km = 3338 min⁻¹mM⁻¹; Kd = 5.4 µM), followed by CYP11B1 (741 min⁻¹mM⁻¹; Kd = 17.7 µM) and CYP11A1 (46 min⁻¹mM⁻¹; no binding spectrum by surface plasmon resonance). These adrenal mitochondrial CYP enzymes produce hydroxylated metabolites that serve as precursors to the long-term epoxide metabolites targeted in WADA testing. CYP46A1 in the brain converts tbol to 16β-hydroxy-OT as the sole product; the physiological significance of this brain enzyme interaction at oral performance doses is unknown but CYP46A1 is involved in cholesterol homeostasis and neurosteroid regulation.
The long-term metabolite (LTM) detection mechanism exploits the conversion of tbol metabolites to epoxide-containing species during metabolic processing. These tbol-specific epoxide structures have an extremely long urinary half-life, persisting for 9–45 days from a single 5 mg dose (Loke et al. 2021) and far longer at performance doses. The presence of these unique epoxide structures allows unambiguous identification of tbol exposure even from decades-old preserved urine samples, enabling the retroactive medal revocations that characterized anti-doping enforcement in the 2000s and 2010s.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
The GDR program exposed roughly 10,000 athletes to Oral-Turinabol between 1968 and 1989, with reported doses from 5 to 35 mg/day.
Useful for historical adoption, female virilization, and athletic-performance context, but not an ethical prospective dosing study.
Controlled administration data detected tbol-specific long-term metabolites for 9.9–44.9 days after a single 5 mg dose.
The article extrapolates longer detection risk at 20–80 mg/day performance cycles; that longer window is a practical anti-doping inference, not the directly measured single-dose result.
Community bloodwork reports describe ALT/AST elevation to 2–3× ULN by week 4, with roughly 5× ULN reported at 80 mg/day by week 6.
Supports the article's monitoring rule, but the exact denominator, lab methods, and co-exposures are not standardized.
The article describes HDL suppression of 15–25% and LDL increases of 10–20% across multiple bloodwork reports.
This scopes lipid-risk claims to community reports rather than controlled cardiovascular outcome trials.
Community outcomes commonly cluster around 4–8 lb lean mass retained after 6–8 weeks at 40–60 mg/day, with one cited recomp shorthand of 1 lb scale gain and 1 inch waist reduction over 3 weeks at 50 mg/day.
Useful for practical expectation-setting, but not a controlled lean-mass measurement; diet, training, stack design, and product quality are uncontrolled.
The article cites Herburger bioassay data showing anabolic potency 57.9–255.5% relative to testosterone with androgenic potency of 6–9%.
Mechanistic potency ratios help explain the anabolic:androgenic framing, but they do not translate directly into modern human performance dosing.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.